<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03051178</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201602458</org_study_id>
    <nct_id>NCT03051178</nct_id>
  </id_info>
  <brief_title>Wearable Sensor for Responsive DBS for ET</brief_title>
  <official_title>Wearable Sensor Driven Closed-loop Deep Brain Stimulation for Essential Tremor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is evaluate the effectiveness and safety of a possible new
      treatment for Essential Tremor (ET) using external wearable sensors, which have the
      capability of recording acceleration and Electromyography (EMG). This therapy is called
      Responsive Deep Brain Stimulation (R-DBS). R-DBS systems will communicate with a computer,
      and apply stimulation when the computer detects patterns associated with tremor. This
      detection will suppress pathological activity and improve or alleviate the tremor.

      Currently, DBS is approved for the treatment of ET; however, stimulation is delivered
      continuously even when tremor or other symptoms are absent. Continuous DBS can lead to
      unwanted side effects such as stuttering and gait\balance problems. On the other hand, R-DBS
      will turn on only if activity associated with ET from the external sensors is detected.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall purpose of this application is to capture pathological activity related to
      essential tremor using external wearable sensors to responsively initiate or terminate DBS.
      To this end, we propose to use the Nexus-D system, which requires a firm ware update to an
      Activa Implantable Neurostimulator (INS), and it will in a smart way turn DBS on/off in
      patients. We will recruit subjects with Activa Single Channel (SC) implants during 6
      post-operative programming visits. Our research group is already familiar with and is in
      possession of the Nexus-D system, and we have successfully performed responsive DBS in two
      patients with Tourette syndrome (TS) and in four patients with Parkinson's disease in acute
      settings. Our lab is also equipped with wireless wearable sensor and amplifier systems, such
      as a 16-unit wireless EMG+ acceleration+inertia Trigno Wireless Bio Acquisition System
      (Delsys Inc, Natick, MA). We aim to combine these signal modalities to capture pathological
      symptoms and generate commands to initiate or terminate DBS (also record adverse side
      effects, if any). Our goal is to characterize the clinical efficacy, side effect profile, and
      battery life of closed-loop DBS in acute settings using wearable sensors in essential tremor
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Rating Scale for Tremor (CRST)</measure>
    <time_frame>6 months post-op</time_frame>
    <description>Responsive deep brain stimulation as an effective alternative to continuous deep brain stimulation Clinical scores during continuous stimulation will be compared to scores on the during closed-loop stimulation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Rating Scale for Tremor (CRST)</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Responsive deep brain stimulation as an effective alternative to continuous deep brain stimulation Clinical scores during continuous stimulation will be compared to scores on the during closed-loop stimulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Rating Scale for Tremor (CRST)</measure>
    <time_frame>24 months post-op</time_frame>
    <description>Responsive deep brain stimulation as an effective alternative to continuous deep brain stimulation Clinical scores during continuous stimulation will be compared to scores on the during closed-loop stimulation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Essential Tremor</condition>
  <arm_group>
    <arm_group_label>Subjects with Essential Tremor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This cohort will receive deep brain stimulation (DBS) therapy responsively based on the level of their symptoms as detected by wearable EMG and inertia (acceleration) sensors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Responsive deep brain stimulation</intervention_name>
    <description>Responsive deep brain stimulation (R-DBS) therapy will be delivered responsively based on the level of their symptoms as detected by wearable EMG and inertia (acceleration) sensors.</description>
    <arm_group_label>Subjects with Essential Tremor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  You provide informed consent.

          -  You are over 21 years of age.

          -  You are diagnosed with a postural-intention (essential) tremor for at least 3 years
             and meet strict diagnostic criteria and have been seen and examined by a movement
             disorders fellowship trained neurologist.

          -  You have had a significant disabling medical-refractory upper extremity tremor with no
             evidence of supraspinal central nervous system disease or injury (tremor not
             adequately controlled by medications for at least three (3) months before implant).

          -  You have had a postural or kinetic tremor severity score of at least 3 out of 4 in the
             extremity intended for treatment on the Fahn-Tolosa-Marin Clinical Rating Scale for
             Tremor (CRST).

          -  You have had a CRST score of 2 or above in any one of the items 16-23 from the
             Disability subsection of the CRST: speaking, feeding other than liquids, bringing
             liquids to mouth, hygiene, dressing, writing, working and social activities.

          -  Your tremor is refractory adequate with trials of at least two medications, one of
             which should be either propranolol or primidone. An adequate medication trial is
             defined as a therapeutic dose of each medication or the development of side effects as
             the medication dose is titrated.

          -  You are available for appropriate follow-up times for the length of the study.

        Exclusion Criteria:

          -  Any previous neurosurgical intervention including deep brain stimulation or ablative
             brain lesions.

          -  Medication related movement disorders.

          -  Any suspicion of Parkinsonian tremor, including presence of Parkinsonian features such
             as bradykinesia, rigidity, or postural instability.

          -  Any behaviors consistent with ethanol or substance abuse as defined by the criteria
             outlined in Diagnostic and Statistical Manual of Mental Disorders (DSM)-V.

          -  Severe medical co-morbidity including cardiovascular disorder, lung disorder, kidney
             disease, continuous neurological disease, hematological disease, or frailty that
             impact tolerability of the surgery as judged by the screening physicians.

          -  Any known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or
             Magnevist) including advanced kidney disease.

          -  Abnormal brain MRI including hydrocephalus, stroke, structural lesions, demyelinating
             lesions, or infectious lesions. Also excluded will be subjects with severe atrophy.

          -  Any uncontrolled symptoms or signs of increased intracranial pressure (e.g., headache,
             nausea, vomiting, lethargy, papilledema).

          -  A history of seizures within the past year.

          -  A dementia rating scale score (DRS) &lt;130 signifying significant cognitive dysfunction
             and a potential for inability to cooperate with tasks involved in the study.

          -  Any attempt or intent of suicide in the last six months.

          -  Presence or history of psychosis.

          -  Significant or active mood disorders including depression. For the purpose of this
             study, we consider a significant mood disorder to include any subject who has:

               -  Scores â‰¥ 20 on the Patient Health Questionnaire - 9 (PHQ-9).

               -  Currently under the care of a psychiatrist

               -  Currently participating in cognitive-behavioral therapy

               -  Been hospitalized for the treatment of a psychiatric illness within 12 months

               -  Ever received transcranial magnetic stimulation

               -  Ever received electroconvulsive therapy

          -  In addition, patients who are pregnant or plan to become pregnant will be excluded
             from this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aysegul Gunduz, PhD</last_name>
    <phone>3522736877</phone>
    <email>agunduz@ufl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Segura</last_name>
    <phone>(352) 273-5566</phone>
    <email>Julie.Segura@neurology.ufl.edu</email>
  </overall_contact_backup>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2017</study_first_submitted>
  <study_first_submitted_qc>February 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2017</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

